198 related articles for article (PubMed ID: 24438238)
1. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma.
Li R; Gao K; Luo H; Wang X; Shi Y; Dong Q; Luan W; You Y
J Exp Clin Cancer Res; 2014 Jan; 33(1):9. PubMed ID: 24438238
[TBL] [Abstract][Full Text] [Related]
2. An integrated mRNA and microRNA expression signature for glioblastoma multiforme prognosis.
Xiong J; Bing Z; Su Y; Deng D; Peng X
PLoS One; 2014; 9(5):e98419. PubMed ID: 24871302
[TBL] [Abstract][Full Text] [Related]
3. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
5. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
6. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.
Ma X; Yoshimoto K; Guan Y; Hata N; Mizoguchi M; Sagata N; Murata H; Kuga D; Amano T; Nakamizo A; Sasaki T
Neuro Oncol; 2012 Sep; 14(9):1153-62. PubMed ID: 22844109
[TBL] [Abstract][Full Text] [Related]
7. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.
Qiu S; Lin S; Hu D; Feng Y; Tan Y; Peng Y
J Transl Med; 2013 Jan; 11():10. PubMed ID: 23302469
[TBL] [Abstract][Full Text] [Related]
8. RNA sequencing and Immunohistochemistry Reveal
Esteve-Codina A; Alameda F; Carrato C; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Dabad M; Tortosa A; Del Barco S; Capellades J; Puig J; Gallego O; Pujol T; Oleaga L; Gil-Gil M; de Quintana-Schmidt C; Valduvieco I; Martinez-Cardús A; Bellosillo B; Muñoz-Marmol AM; Esteve A; Domenech M; Camins A; Craven-Bartle J; Villa S; Marruecos J; Domenech S; de la Iglesia N; Balana C
Clin Cancer Res; 2021 Jan; 27(2):645-655. PubMed ID: 33106291
[TBL] [Abstract][Full Text] [Related]
9. A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.
Kang EM; Yin AA; He YL; Chen WJ; Etcheverry A; Aubry M; Barnholtz-Sloan J; Mosser J; Zhang W; Zhang X
CNS Neurosci Ther; 2019 Sep; 25(9):937-950. PubMed ID: 31016891
[TBL] [Abstract][Full Text] [Related]
10. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
[TBL] [Abstract][Full Text] [Related]
11. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
12. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
13. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
14. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
15. Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
Sathyan P; Zinn PO; Marisetty AL; Liu B; Kamal MM; Singh SK; Bady P; Lu L; Wani KM; Veo BL; Gumin J; Kassem DH; Robinson F; Weng C; Baladandayuthapani V; Suki D; Colman H; Bhat KP; Sulman EP; Aldape K; Colen RR; Verhaak RG; Lu Z; Fuller GN; Huang S; Lang FF; Sawaya R; Hegi M; Majumder S
J Neurosci; 2015 Nov; 35(45):15097-112. PubMed ID: 26558781
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes.
Gulluoglu S; Tuysuz EC; Sahin M; Kuskucu A; Kaan Yaltirik C; Ture U; Kucukkaraduman B; Akbar MW; Gure AO; Bayrak OF; Dalan AB
Brain Res; 2018 Dec; 1700():199-210. PubMed ID: 30176243
[TBL] [Abstract][Full Text] [Related]
17. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
Yerukala Sathipati S; Huang HL; Ho SY
BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characterization of Renal Cell Carcinoma: A Potential Three-MicroRNA Prognostic Signature.
Lokeshwar SD; Talukder A; Yates TJ; Hennig MJP; Garcia-Roig M; Lahorewala SS; Mullani NN; Klaassen Z; Kava BR; Manoharan M; Soloway MS; Lokeshwar VB
Cancer Epidemiol Biomarkers Prev; 2018 Apr; 27(4):464-472. PubMed ID: 29440068
[No Abstract] [Full Text] [Related]
19. Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas.
Wong N; Khwaja SS; Baker CM; Gay HA; Thorstad WL; Daly MD; Lewis JS; Wang X
Cancer Med; 2016 Jul; 5(7):1619-28. PubMed ID: 27109697
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy.
Schnabel E; Knoll M; Schwager C; Warta R; Mock A; Campos B; König L; Jungk C; Wick W; Unterberg A; Debus J; Herold-Mende C; Abdollahi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
